UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma (Nasdaq: URGN) has announced the issuance of inducement restricted stock units (RSUs) to 7 new employees. The RSUs, convertible into up to 18,500 ordinary shares, will vest equally over three years, with one-third vesting annually on the vesting date anniversary. These new hires will support the commercialization of Jelmyto® (mitomycin), the company's first approved product for pyelocalyceal solution, and aid in pipeline development. The grants were made under UroGen's 2019 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
UroGen Pharma (Nasdaq: URGN) ha annunciato l'emissione di unità di azioni vincolate (RSU) come incentivo per 7 nuovi dipendenti. Le RSU, convertibili in un massimo di 18.500 azioni ordinarie, si matureranno in modo equo nel corso di tre anni, con un terzo che matura annualmente alla data di anniversario della maturazione. Questi nuovi assunti supporteranno la commercializzazione di Jelmyto® (mitomicina), il primo prodotto approvato dall'azienda per la soluzione pielocaliceale, e contribuiranno allo sviluppo del pipeline. I conferimenti sono stati effettuati nell'ambito del Piano di Incentivazione del 2019 di UroGen e sono conformi alla Regola di Quotazione 5635(c)(4) di Nasdaq.
UroGen Pharma (Nasdaq: URGN) ha anunciado la emisión de unidades de acciones restringidas por incentivo (RSUs) a 7 nuevos empleados. Las RSUs, convertibles en hasta 18,500 acciones ordinarias, se consolidarán de manera equitativa durante tres años, con un tercio consolidándose anualmente en la fecha del aniversario de consolidación. Estas nuevas contrataciones apoyarán la comercialización de Jelmyto® (mitomicina), el primer producto aprobado de la compañía para solución pielocaliceal, y ayudarán en el desarrollo de la cartera de productos. Las concesiones se realizaron bajo el Plan de Incentivo de 2019 de UroGen y cumplen con la Regla de Cotización 5635(c)(4) de Nasdaq.
UroGen Pharma (Nasdaq: URGN)은 7명의 신규 직원에게 유인 제한 주식 단위(RSU)를 발행했다고 발표했습니다. RSU는 최대 18,500주로 전환 가능하며, 3년에 걸쳐 균등하게 분배되며, 1/3은 매년 성취일 기념일에 맞춰 분배됩니다. 이 새로운 직원들은 Jelmyto® (미토마이신)의 상용화를 지원하고 파이프라인 개발에 도움을 줄 것입니다. 이 보상은 UroGen의 2019 유인 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
UroGen Pharma (Nasdaq: URGN) a annoncé l'émission d'unités d'actions restreintes incitatives (RSU) à 7 nouveaux employés. Les RSU, convertibles en jusqu'à 18 500 actions ordinaires, seront acquises de manière égale sur trois ans, avec un tiers acquérant chaque année à la date anniversaire de l'acquisition. Ces nouvelles recrues soutiendront la commercialisation de Jelmyto® (mitomycine), le premier produit approuvé de l'entreprise pour la solution pyélocalicielle, et aideront au développement du pipeline. Les attributions ont été faites dans le cadre du Plan d'Incentive 2019 de UroGen et sont conformes à la Règle de Cotation 5635(c)(4) de Nasdaq.
UroGen Pharma (Nasdaq: URGN) hat die Ausgabe von Anreiz-beschränkten Aktieneinheiten (RSUs) an 7 neue Mitarbeiter bekannt gegeben. Die RSUs, die in bis zu 18.500 Stammaktien umgewandelt werden können, werden gleichmäßig über drei Jahre verteilt, wobei ein Drittel jährlich am Jahrestag des Vestings fällig wird. Diese neuen Mitarbeiter werden die Kommerzialisierung von Jelmyto® (Mitomycin), dem ersten genehmigten Produkt des Unternehmens für pielokalyzeale Lösungen, unterstützen und zur Entwicklung der Pipeline beitragen. Die Zuwendungen wurden im Rahmen des Anreizplans von UroGen aus dem Jahr 2019 gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- New hires strengthen commercialization team for approved product Jelmyto
- Employee retention incentives through 3-year vesting RSUs
- Potential shareholder dilution from 18,500 new shares
Up to 18,500 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.
The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product Jelmyto® (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in
Jelmyto®, RTGel® and UroGen® are registered trademarks of UroGen Pharma Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250307402285/en/
INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588
MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3583
Source: UroGen Pharma Ltd.
FAQ
How many UroGen Pharma (URGN) shares are issuable under the new RSU grants?
What is the vesting schedule for UroGen's new employee RSU grants?
How many new employees received RSU grants from UroGen Pharma?
What product will the new UroGen employees support commercializing?
